文献速递前列腺癌肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

评估立体定向体部放疗用于寡转移性泌尿生殖系统肿瘤转移灶定向治疗作用的前瞻性试验综述

Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
PubMed 文献 · Eur Urol Oncol · 2022-10-22

本文对PubMed和ClinicalTrials.gov于2022年4月进行的关键综述,结合专家意见,评估立体定向体部放疗(SBRT)作为转移灶定向治疗(MDT)在寡转移性前列腺癌、肾癌或膀胱癌中的前瞻性研究。SBRT最常研究的应用是异时性寡复发激素敏感性前列腺癌(HSPC),与高局部控制率和极低毒性风险相关;从肿瘤不可知角度看,SBRT对寡转移性疾病(OMD)的临床获益与延长总生存的能力相关。需进一步前瞻性研究明确SBRT在延迟下次治疗时间或与其他全身治疗协同中的作用,并扩展按肿瘤组织学和寡转移状态分层的前瞻性研究以指导最佳患者选择和治疗策略。

要点

  • SBRT用于异时性寡复发HSPC与高局部控制率和极低毒性风险相关。
  • 从肿瘤不可知角度看,SBRT对OMD的临床获益与延长总生存的能力相关。
  • 需进一步前瞻性研究明确SBRT在延迟下次治疗或与全身治疗协同中的作用。

核心结论

  • SBRT与高局部控制率和极低毒性风险相关,多项试验评估了MDT单独用于寡复发HSPC。
  • 从肿瘤不可知角度看,SBRT对OMD的临床获益与延长总生存的能力相关。
  • 需扩展前瞻性研究评估SBRT MDT,按肿瘤组织学和寡转移状态分层,以指导最佳患者选择和治疗策略。

研究设计与样本

  • 对PubMed和ClinicalTrials.gov于2022年4月进行的关键综述,遵循PRISMA声明,结合专家意见,识别评估SBRT用于寡转移性前列腺癌、肾癌或膀胱癌的前瞻性研究。

主要发现

  • SBRT最常研究的应用是异时性寡复发激素敏感性前列腺癌(HSPC)。
  • SBRT与高局部控制率和极低毒性风险相关,多项试验评估了MDT单独用于寡复发HSPC。
  • 从肿瘤不可知角度看,SBRT对OMD的临床获益与延长总生存的能力相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 指导SBRT作为替代标准治疗应用的前瞻性数据仍有限。
  • 需进一步前瞻性研究明确SBRT在延迟下次治疗时间或诱导与其他全身治疗协同中的作用。
  • 需扩展前瞻性研究评估SBRT MDT,按肿瘤组织学和寡转移状态分层,以指导最佳患者选择和治疗策略。
  • 仍需大量工作明确SBRT单独与其他标准治疗在前列腺癌中的比较,或SBRT在寡转移性肾癌和膀胱癌中肿瘤控制或延迟下次治疗的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Emerging evidence supports the use of stereotactic body radiation therapy (SBRT) as metastatic-directed therapy (MDT) for oligometastatic genitourinary cancers; however, the prospective data to guide its application as an alternative standard of care remain limited. OBJECTIVE: To review prospective trials that assess the role of SBRT for patients with genitourinary cancers within a modern framework of oligometastatic disease (OMD) and to highlight clinical scenarios where SBRT may offer a benefit to patients with metastatic cancer. EVIDENCE ACQUISITION: We performed a critical review of PubMed and clinicaltrials.gov in April 2022 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, combined with expert input to identify prospective studies investigating the role of SBRT for oligometastatic prostate, renal, or bladder cancer. EVIDENCE SYNTHESIS: The most commonly studied application of SBRT has been for metachronous oligorecurrent hormone-sensitive prostate cancer (HSPC). Further prospective study is needed to define the role of SBRT in delaying time to next therapy or inducing synergy with other systemic therapies. CONCLUSIONS: SBRT has been associated with high rates of local control and minimal risk of toxicity with multiple trials assessing an MDT-alone approach for oligorecurrent HSPC. From a tumor-agnostic perspective, the clinical benefit of SBRT for OMD has been associated with the ability to extend overall survival. As methods of cancer detection and treatment evolve, expansion of studies that prospectively evaluate SBRT MDT, stratifying by tumor histology and oligometastatic state, is needed to inform optimal patient selection and treatment strategy. PATIENT SUMMARY: We review outcomes from prospective trials assessing the role of stereotactic body radiation therapy (SBRT) for oligometastatic genitourinary cancers, which have predominantly investigated SBRT for oligorecurrent prostate cancer. Much work remains to define how SBRT alone compares with other standard of care treatments for prostate cancer or the role of SBRT in tumor control or delaying time to next therapy in oligometastatic renal and bladder cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Huynh MA, Tang C, Siva S, et al. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers. Eur Urol Oncol. 2022. PMID: 36283936. doi:10.1016/j.euo.2022.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。